Plasma EGFR results for lung cancer patients whose tissue sample fell short
TL;DR Plasmora runs one blood test well - EGFR mutation testing on plasma for people with non-small cell lung cancer, aimed at oncology centres outside the metros. It serves two moments, when the biopsy left too little tissue and when a patient on targeted therapy starts to progress. Oncology centres refer, and patients mostly pay.
Whether a lung cancer patient gets a cheap daily tablet or chemotherapy often depends on one gene. In an AIIMS Delhi cohort, 57% of untreated patients tested had an EGFR mutation in their tissue[1]. Getting that answer needs enough tumour tissue, and lung biopsies are small and risky to repeat. The problem returns at relapse. In the same cohort, a resistance mutation called T790M showed up in the plasma of 61% of patients already on EGFR tablets, and the authors judged that blood testing could spare more than 60% of them a second biopsy[1]. Outside large cities, getting the test often means shipping samples to a metro lab and waiting.
What it does, in regulatory terms: a laboratory diagnostic test that informs treatment selection by the oncologist. It is not cancer screening and makes no claim to find cancer early. It runs on licensed IVD kits under the CDSCO medical device rules.
Here's how it works. Plasmora places blood-collection tubes and trained phlebotomy at partner oncology centres in tier-2 cities, moves samples cold-chain to one accredited molecular lab, and runs a validated PCR assay for the common EGFR mutations. Reports go to the oncologist with a plain note on what a negative result means. Plasma misses some true mutations, so a negative result triggers advice to retest on tissue.
I reframed the seed, which pitched AI liquid biopsy to catch cancer early. Multi-cancer blood tests are still unproven on hard outcomes, and the NHS-Galleri trial missed its main goal of cutting late-stage diagnoses[2]. A narrow test with a clear treatment decision behind it is a business a small team can build now.
Patients and families pay most of the bill in private oncology, with the oncologist choosing the test. I found no published Indian price for a plasma EGFR test, so pricing has to come from quotes collected during validation. Second payers to explore are hospital oncology departments that want results inside their own walls, and drug makers whose patient programmes sometimes fund testing. Treat that last one as a hypothesis.
The evidence for plasma EGFR testing in Indian patients is published. A Delhi study of 184 patients found one commercial plasma assay picked up 97.1% of tissue-confirmed mutations[3], and a 2024 meta-analysis of 22 studies found close agreement between blood and tissue[4]. The 2026 trial results on screening tests[2] push serious money toward treatment-linked uses instead.
There's no public figure for the number of plasma EGFR tests run in India each year. The narrow signal is clinical - more than half of untreated patients in one Indian cohort carried the mutation[1], and most patients on EGFR tablets eventually need a resistance check. Adjacent - Indian cancer-genetics labs already sell wide liquid biopsy panels, which shows oncologists will order blood-based tests[5][6].
One cancer-genetics lab sells blood-based screening, diagnosis and tracking tests[5]. A precision-oncology firm offers ctDNA liquid profiling and a combined tissue-and-liquid panel[6]. Large genomics labs and hospital labs in metros run EGFR tests too. These players sell broad panels from big-city labs. The gap is a fast, single-question test with pickup built into tier-2 oncology centres, priced below a full panel.
| Difficulty | Hard (56/100) |
| Starting capital | ₹1.4–2.6 Cr |
| Time to launch | 8–12 months |
The science is settled, but the lab and the logistics are not. You need a molecular lab with tight contamination control, a validation study against tissue, accreditation, and cold-chain pickup that gets plasma processed in time. Winning oncologists' trust takes published concordance data from your own lab.
Yes. This is a clinical molecular lab using regulated kits.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
AI must not suggest treatment or call a result from incomplete data. The oncologist chooses therapy, and every report is signed by a qualified person in the lab.
Want to work out the AI layer for Plasmora? Talk to Yash →
I like this for a founder with a molecular pathology partner and oncology relationships in two or three tier-2 cities. If you're hoping to build a cancer-screening brand then skip it. Prove two things first - that your lab matches tissue results on 100 paired samples, and that five oncology centres send you samples every week.
Plan for roughly ₹1.4–2.6 Cr for the molecular lab, kits, staff and accreditation work.
Use CDSCO-licensed IVD kits, register where your state requires it, aim for NABL accreditation and follow the DPDP Act.
Yes. Check the local lab accreditation and IVD rules before you open. Oncologists anywhere will want to see your concordance data first.
The free Plasmora validation kit has the line-by-line capital breakdown, the effort scoring, the lab licensing and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for oncologists and lab partners, and 5 assumptions to test. Download the kit →
Thinking about building Plasmora or something close to it? The make-or-break work is a paired-sample validation that oncologists will believe and a pickup chain that keeps plasma usable, and that's the kind of plan I help founders put together. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.